Skip to main content

Table 6 Summary of adverse events by treatment

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Preferred term MET BID RE BID MET + RE BID
N = 13 N = 13 N = 13
n (%) n (%) n (%)
Any Event 5 (38%) 2 (15%) 7 (54%)
Headache 2 (15%) 0 1 (8%)
Back pain 2 (15%) 0 0
Muscle spasms 1 (8%) 1 (8%) 0
Hypoglycemia 1 (8%) 0 1 (8%)
Neck pain 1 (8%) 0 0
Osteoarthritis 0 0 1 (8%)
Abdominal pain upper 0 1 (8%) 0
Dyspepsia 0 0 1 (8%)
Toothache 1 (8%) 0 0
Dizziness 1 (8%) 0 0
Fatigue 1 (8%) 0 0
Nasopharyngitis 0 0 1 (8%)
Wound 0 0 1 (8%)
Rash 0 0 1 (8%)